ImmunityBio's ANKTIVA Now Available To Patients Through Both Commercial And Government Insurance Programs, Also Announced Plans To Expand Its Bladder Cancer Program Globally, Notably In The European Union And India
ImmunityBio's ANKTIVA Now Available To Patients Through Both Commercial And Government Insurance Programs, Also Announced Plans To Expand Its Bladder Cancer Program Globally, Notably In The European Union And India
ImmunityBio的ANKTIVA现在可以通过商业和政府保险计划提供给患者，还宣布计划在全球范围内扩大其膀胱癌项目，尤其是在欧盟和印度。
ANKTIVA reaches U.S. commercial and Medicare insurance coverage milestone within three months of FDA approval
ANKTIVA在FDA批准后三个月内达到了美国商业和医疗保险覆盖的里程碑。
- Global expansion of commercial and clinical bladder cancer programs
- Filing process initiated with European Medicines Agency (EMA) for regulatory approval of ANKTIVA in European Union countries
- Global filing for BCG naïve trial initiated (QUILT-2.005) in India
- ANKTIVA Non-Small Cell Lung Cancer (NSCLC) FDA meeting held in June 2024
- 扩大商业和临床膀胱癌计划的全球范围。
- 已向欧洲药品管理局（EMA）提出ANKTIVA在欧盟国家的监管批准申请程序。
- 在印度启动了BCG未接种试验的全球申报（QUILt-2.005） 。
- 2024年6月举行了关于ANKTIVA非小细胞肺癌（NSCLC）的FDA会议。
ImmunityBio, Inc. ((IBRX), today announced significant progress in market access, making ANKTIVA (nogapendekin alfa inbakicept-pmln) widely available to patients through both commercial and government insurance programs. The company also announced plans to expand its bladder cancer program globally, notably in the European Union and India.
ImmunityBio, Inc.（IBRX）今天宣布，在市场准入方面取得了重大进展，并通过商业和政府保险计划使ANKTIVA（nogapendekin alfa inbakicept-pmln）广泛可用于患者，该公司还宣布计划在全球范围内扩展其膀胱癌计划，尤其是在欧盟和印度。